AltStreet
EDGAR Verified
Primary Source · SEC.gov

Ishara Biotech Fund LP

Fund Vehicle2026 vintage506(b), 3(c)(1)
Latest signalInvestors increasedForm D/A · 2026-01-203 events: 1 investors increased, 1 sold increased, 1 new form d filerLast filing 2026-01-20

Raised

$8M

Investors

11

Min Invest

None stated

AltStreet Analysis

·

Generated from EDGAR primary sources

Ishara Biotech Fund LP is a Delaware limited partnership that has raised $8.5M from 11 investors under Rule 506(b) and Section 3(c)(1). This amended filing reports activity for a pooled investment fund focused on longevity biotechnology, managed by Ishara Partners GP, LLC and affiliated entities including executive officer Shaun Mehra. Minimum investment amount was not disclosed on the filing.

This longevity biotech fund follows the typical 506(b) / 3(c)(1) exemption pattern common to private life sciences funds targeting accredited investors. With $8.5M raised from 11 investors, the average commitment of approximately $773K suggests an institutional or high-net-worth investor base, consistent with early-stage biotech venture funds in this category.

Data Flags

related personsTwo executive officer entities listed (Ishara Partners GP, LLC and Ishara Investments LP) in addition to individual Shaun Mehra, suggesting a multi-layered GP structure
generalPlatform description indicates 0 related EDGAR entities despite presence of multiple affiliated entities (GP, Ishara Investments LP) listed in the filing

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002052609
Entity NameIshara Biotech Fund LP
ExemptionRule 506(b), Section 3(c), Section 3(c)(1)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(1) of the Investment Company Act: the fund is excluded from investment-company registration because it has no more than 100 beneficial owners.
Entity TypeLimited Partnership
Jurisdiction of OrganizationDelaware
Issuer Address4412 Romero Drive, Tarzana, CA 91356
Phone(818) 983-4448
Industry / Fund TypePooled Investment Fund · Hedge Fund
Investment Company ActExcluded under Section 3(c)(1) (100 beneficial owners or fewer)
Securities TypePooled Investment Fund
First Sale Date—
Filing DateJanuary 20, 2026
Accession Number0001104659-26-005001
Total Offering AmountIndefinite
Total Amount Sold$8,491,000
Total Investors11
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationIntended to last more than one year
Sales Commissions$0
Finders' Fees$0
Net Asset Value RangeDecline to Disclose
State (Issuer Address)CA
Amendment Count1 amendments filed

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

D/AJanuary 20, 2026DJanuary 17, 2025

Capital Raise Timeline

2 Form D filings from Jan 17, 2025 to Jan 20, 2026, the latest a D/A.

Checking access…

In the Terminal

Filing events

3

latest Jan 20, 2026

Critical / warning

0 / 0

0 watch · 3 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

raising

Latest event Investors increase · Jan 20, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 3 filing events with values and deltas, latest 2026-01-20, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Regulatory Activity

Filing events on this entity detected by AltStreet's EDGAR monitoring.

Jan 2026Form D amendment
SEC.gov
Jan 2026Form D amendment
SEC.gov

Signal analysis reserved for subscribers

Severity grading, value-change deltas, and analyst notes on these filings ship in the AltStreet newsletter and the Pro terminal.

Get the signal feed

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

N/A Ishara Partners GP, LLC

Executive Officer · Los Angeles, CA

N/A Ishara Investments LP

Executive Officer · Los Angeles, CA

Shaun Mehra

Executive Officer · Los Angeles, CA

Questions About Ishara Biotech Fund LP

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Ishara Biotech Fund LP?

Ishara Biotech Fund LP is a Delaware limited partnership that filed a Form D with the SEC on January 20, 2026 as a hedge fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(1) for an offering of pooled investment fund interests. AltStreet links the issuer to Ishara Biotech Fund LP.

Is Ishara Biotech Fund LP legit?

AltStreet does not rate legitimacy; it reports the public record. Ishara Biotech Fund LP filed a Form D with the SEC on January 20, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(1). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $8,491,000 sold to 11 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. The issuer is linked to Ishara Biotech Fund LP, which AltStreet has reviewed. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Ishara Biotech Fund LP registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Ishara Biotech Fund LP claimed Rule 506(b), Section 3(c), Section 3(c)(1) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Ishara Biotech Fund LP raised?

Ishara Biotech Fund LP reported $8,491,000 sold from 11 investors in an offering of indefinite size as of the Form D filed January 20, 2026.

Who can invest in Ishara Biotech Fund LP?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(1), it may have no more than 100 beneficial owners. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Ishara Biotech Fund LP?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Ishara Biotech Fund LP and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Ishara Biotech Fund LP?

The Form D lists 3 related persons: Ishara Partners GP, LLC, executive officer (General Partner of the Issuer); Ishara Investments LP, executive officer (Investment Manager to the Issuer); Shaun Ravi Mehra, executive officer (Portfolio Manager). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Ishara Biotech Fund LP located?

The issuer's address on its SEC filings is 4412 Romero Drive, Tarzana, CA 91356. Its phone number of record is (818) 983-4448. It is organized under the laws of Delaware.

How long is the Ishara Biotech Fund LP offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

How large is Ishara Biotech Fund LP?

The issuer declined to disclose its net asset value range on the Form D, which the form permits.

Is this your offering?

Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.

Claim Profile — FreeGet Verified — $2,400/yr

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.